MedTrace Logo

A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)

NCT05818553 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2026-01-29

No results posted yet for this study

Summary

A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)

Conditions

  • SCN2A Encephalopathy
  • SCN8A Encephalopathy

Interventions

DRUG

PRAX-562

Once daily oral or G-tube treatment.

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Praxis Precision Medicines

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-02
Primary Completion
2025-11-12
Completion
2027-03-01
FDA Drug
Yes

Countries

  • United States
  • Israel
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05818553 on ClinicalTrials.gov